Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.56 |
| ▸ | SELP | P16109 | 7/20 | 0.51 |
| ▸ | MAG | P20916 | 4/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.50 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30649207 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30649952 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30650122 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30651291 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30651920 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL31126371 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL29359311 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL20971391 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL22969674 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30650374 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622932-B2 | Immunomodulatory cells and uses thereof | SINAI HEALTH SYSTEM (CA) | 2026-05-12 | — | — | US | claimed |
| US-20250326839-A1 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4019958-B1 | QUANTIFICATION METHOD OF HEX4, LYSO-GM1, FUC-GLCNAC-ASN, AND LYSO-SULFATAIDE INCLUDED IN CEREBROSPINAL FLUID | JAPAN CHEM RES (JP) | 2025-09-24 | — | — | EP | claimed |
| US-20250282866-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-09-11 | — | — | US | claimed |
| EP-3972643-B1 | ANTAGONISTS OF THE COMPLEMENT SYSTEM FOR USE IN METHODS OF TREATING PARAPROTEINEMIC NEUROPATHIES | argenx BV (BE) | 2025-05-14 | — | — | EP | claimed |
| CN-119959323-A | Ganglioside biological GM1 sensor and preparation method and application thereof | 浙江大学 | 2025-05-09 | — | — | CN | claimed |
| EP-4008347-B1 | GD2 BINDING MOLECULE | UNIV MIE (JP) | 2025-04-30 | — | — | EP | claimed |
| CN-119753110-A | Adapter for characterizing analytes, characterization method and use thereof | 北京齐碳科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2025056467-A1 | POLYPHOSPHOESTER STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | claimed |
| WO-2025056466-A1 | POLYVINYLPYRROLIDONE STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | claimed |
| EP-4023068-A1 | DRUG, DRUG MANUFACTURING METHOD, AND WATER PURIFICATION METHOD | Acenet Inc. (JP) | 2022-07-06 | — | — | EP | claimed |
| EP-4019958-A1 | QUANTIFICATION METHOD OF HEX4, LYSO-GM1, FUC-GLCNAC-ASN, AND LYSO-SULFATAIDE INCLUDED IN CEREBROSPINAL FLUID | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-06-29 | — | — | EP | claimed |
| US-20220178937-A1 | QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID | JCR PHARMACEUTICALS CO., LTD. (JP) | 2022-06-09 | — | — | US | claimed |
| WO-2022120390-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| EP-4008347-A1 | GD2 BINDING MOLECULE | Mie University (JP) | 2022-06-08 | — | — | EP | claimed |
| EP-4003365-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | Lifescience AS (NO) | 2022-06-01 | — | — | EP | claimed |
| CN-114501996-A | Chemical, method for producing chemical, and method for purifying water | 株式会社ACENET | 2022-05-13 | — | — | CN | claimed |
| CN-114450026-A | Sialic acid for use in the treatment of psoriasis | 生命科学股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022032293-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622932-B2 | Immunomodulatory cells and uses thereof | TNFRSF9, CD47, PDCD1LG2 | SIGLEC7 277/4885SELP 197/4885MAG 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.